Status
Conditions
Treatments
About
Background:
Trillions of tiny organisms-including bacteria, fungi, and viruses-live inside our intestines. These microorganisms break down nutrients in our food, aid our immunity, and help keep us healthy. The population balances among these organisms can vary in different people due to factors including genetics, lifestyle, and diet. More studies are needed to understand how dietary habits affect our intestinal microorganisms.
Objective:
To see how switching from a traditional Western diet (low in fiber, high in saturated fat) to a Mediterranean-like unprocessed foods diet (CLEAN-MED) changes the environment in the intestine. The CLEAN-MED diet includes lots of vegetables, fruits, and whole grains with little sugar or red meat.
Eligibility:
Healthy adults aged 18 to 60
Design:
Participants will be divided into 2 groups. All will start with a trial week. Participants will log all the food they eat and answer questions about their diet throughout the entire study.
Participants in the short-term group will eat a Western diet for 4 weeks and a CLEAN-MED diet for 4 weeks. Food will be provided for the CLEAN-MED diet. Participants will visit the clinic each week and complete surveys. They will log everything they eat. They will provide blood, urine, and stool samples.
Participants in the long-term group will eat the CLEAN-MED diet for up to 12 months. They will visit the clinic each month and complete surveys. They will log everything they eat. They will provide blood, urine, and stool samples. Some foods will be provided for the first 2 weeks. Participants may choose to have a scan of their body composition every few months.
Full description
Study Description:
This study (called the CLEAN-MED Diet Study) seeks to examine associations between the gut microbiome, well-being, and adherence to a Mediterranean-like unprocessed food diet. The premise of this study is based on the well-known health benefits of a healthy Mediterranean diet and the potential role that the gut microbiota may serve as a factor in health and disease. The study will recruit healthy outpatient adults, who agree to adhere to a strict Mediterranean-like diet with unprocessed foods, meticulously log their food intake and perceived quality of life using provided questionnaires/tools, and who agree to collect periodic biological samples for analysis. The study will consist of: (1) a short-term cohort who will complete a crossover study design with their habitual Western diet for 4 weeks and the intervention Mediterranean-like unprocessed food diet for 4 weeks (with CLEAN-MED diet food provided by the NIH metabolic kitchen), and (2) a long-term cohort who will continuously adhere to the Mediterranean-like unprocessed food diet for 12 months, following assessment of their baseline diet (with some CLEAN-MED diet foods provided for up to the first 2 weeks of the long-term study, after which the participants must provide their own food).
Objectives:
Primary Objective:
-The primary objective is to measure changes within the gut microbiome in healthy adults who adhere to a Mediterranean-like unprocessed food diet plan.
Secondary Objectives:
Tertiary Objective:
-Measure the level of adherence to the diet given a strict request for data submission.
Endpoints:
Primary Endpoint:
-Measure changes in gut microbiota composition and functionality from periodic stool sampling using either 16S rRNA and/or shotgun sequencing.
Secondary Endpoints:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study, at the discretion of the PI:
Current use of medications or dietary supplements for weight or appetite control, whether prescribed or not, including laxatives (within the last 4 weeks)
Currently eating a vegan, vegetarian, keto or other restrictive diet plan, or food allergies that would affect eating the study diet, at the discretion of the PI
Active cardiovascular disease (in past year with myocardial infarction, coronary stent or bypass surgery)
Diabetes (type 1 and 2) or history of gestational diabetes or on hypoglycemic medications or any other indication
Kidney disease (eGFR less than 50 mL/min per 1.73 m^2)
Liver disease (liver transaminase higher than 3 times the normal range for the laboratory)
Symptomatic gallstones
History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision
Has a diagnosed autoimmune condition (i.e. HIV, lupus, etc.) or other immunosuppressive or immunodeficient state, at the discretion of the PI
Musculoskeletal disorders precluding regular physical activity
Consumption of the following drugs: proton pump inhibitors, antidiabetic drugs, cholesterol lowering drugs, SGLT-2 inhibitors, GLP-1 receptor agonist, insulin, Amylin analog, Alpha-glucosidase inhibitor, Dopamine agonist, Bile acid sequestrant, corticosteroids, methotrexate or immunosuppressive cytotoxic agents
Some types of abdominal surgery, including bariatric surgery, or severe intestinal problems (by discretion of study physician), including:
Consumes more than 3 alcoholic beverages per day
Currently receiving or has received antibiotics, antifungals, antivirals, or antiparasitics in past 2 months
Is currently using or has used probiotic supplements within the last 2 months
Is currently on a weight-loss program or has experienced a weight change (gain or loss) of greater than 15 pounds in the past 3 months
Has a history of hospitalization for mental health condition and/or has had a change in depression or anxiety prescription medications within the past 10 weeks (by discretion of study physician)
Is pregnant or breastfeeding or planning pregnancy within the time of the study
Subjects who are not fluent in English
Use of smoking or chewing tobacco, e-cigarettes, cigars, or other nicotine-containing products, or cannabis
Regular use of prescription opiate pain medication
Weight <100 lbs
Acute disease, defined as the presence of a moderate or severe illness with or without fever, at the time of enrollment
Inability to communicate effectively with study personnel
Lack of commitment with the intervention or non-compliance (at the discretion of the investigator)
Eating disorders
Primary purpose
Allocation
Interventional model
Masking
78 participants in 5 patient groups
Loading...
Central trial contact
Crystal K Ayensu; David B Sacks, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal